BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago
ADVERTISEMENT
Market News

Rite Aid swings to profit in Q2, stock gains strength

Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over period, even as revenues growth remained stagnant. The company’ stock jumped over 4% during pre-market hours. Adjusted net profit for the second quarter came in at 12 cents per share, which was higher […]

September 26, 2019 2 min read

Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of
2020, from a loss in the year-over period, even as revenues growth remained stagnant.
The company’ stock jumped over 4% during pre-market hours.

Adjusted net profit for the second quarter came in at 12 cents per share, which was higher than the Wall Street estimate of 7 cents per share.

Rite Aid reported a narrower loss from continuing operations in the fourth quarter
Image Courtesy: Rite Aid

Revenues edged down almost 1% from last year and came in at $5.37
billion. This missed the analysts’ projection of $5.41 billion.

In the Retail Pharmacy segment, revenues edged down 1.6% hurt by store closures, even though same-store sales modestly increased 0.4%. Pharmacy sales have been negatively impacted by new generic introductions.

Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over period, even as revenues growth remained stagnant

Front-end same-store sales, excluding cigarettes and tobacco products, decreased 0.6% year-over-year.

ADVERTISEMENT

Outlook

Looking ahead, the company expects net sales to be in the range of $21.5 billion to $21.9 billion in fiscal 2020 and annual same-store sales growth in the range of 0-1%. Adjusted EPS is expected to be between $0.00 and $0.56. 

READ: Is Lululemon’s bull run coming to an end?

RAD stock has declined 70% in the last one year, and 52% in
the year-to-date period.  The company’s inability to stop its stock from
free fall culminated in CEO John Standley stepping down from the top post last month.

The newly appointed CEO Heyward Donigan has vast experience in the healthcare industry and is on Fortune’s watch list of executives who have the potential to become the world’s most powerful women.

READ: Major IPOs expected in late-2019 or 2020

ADVERTISEMENT

Following failed merger bids with Walgreens (NASDAQ: WBA) and more recently Albertsons, the company is now looking up at the new CEO to save the sinking ship. The stock has slightly recovered since the appointment of Donigan.

Donigan said in a
statement after the earnings announcement, “Our Adjusted EBITDA results
exceeded our plan driven by prescription count growth and strong expense
control. This gives us important momentum for our future, and I look forward to
working closely with our team to deliver a solid finish to our fiscal year and
position Rite Aid as an innovative leader in our industry.”

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT